Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates GlobeNewswire - Tue Nov 12, 6:00AM CST

AUTL : 2.84 (+1.43%)
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) GlobeNewswire - Fri Nov 8, 3:23PM CST

AUTL : 2.84 (+1.43%)
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations GlobeNewswire - Tue Nov 5, 8:00AM CST

AUTL : 2.84 (+1.43%)
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 GlobeNewswire - Mon Oct 28, 4:00PM CDT

AUTL : 2.84 (+1.43%)
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress GlobeNewswire - Wed Oct 16, 8:00AM CDT

AUTL : 2.84 (+1.43%)
AUTL
Chart of the Day: Autolus Therapeutics - Effective Cancer Treatments Barchart - Fri Jan 12, 7:00AM CST

The Chart of the Day belongs to the oncology based biomedical company Autolus Therapeutics (AUTL) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

AUTL : 2.84 (+1.43%)
Why Autolus Therapeutics Stock Is Crashing Today Motley Fool - Fri Dec 9, 2022

Shares of Autolus Therapeutics (NASDAQ: AUTL) were crashing 35.9% as of 10:34 a.m. ET on Friday. The steep decline came after the biopharmaceutical company announced the price of a public stock offering...

AUTL : 2.84 (+1.43%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing FinancialNewsMedia - Wed Oct 5, 2022

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...

ONCY : 0.9800 (-1.85%)
ONC.TO : 1.37 (-2.14%)
SNTI : 2.12 (unch)
INBX : 13.98 (-0.43%)
IMVT : 26.54 (+1.41%)
AUTL : 2.84 (+1.43%)
BMY : 58.23 (+0.60%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing PR Newswire - Wed Oct 5, 2022

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting...

BMY : 58.23 (+0.60%)
ONC.TO : 1.37 (-2.14%)
ONCY : 0.9800 (-1.85%)
SNTI : 2.12 (unch)
INBX : 13.98 (-0.43%)
IMVT : 26.54 (+1.41%)
AUTL : 2.84 (+1.43%)
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022 Globe Newswire - Thu Jul 21, 2022

In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call,...

AUTL : 2.84 (+1.43%)

Barchart Exclusives

1 AI Stock to Buy and Hold for Long-Term Growth Barchart - Thu Nov 21, 7:18PM CST
Pure Storage stands out in AI data storage, bolstered by a new partnership with CoreWeave and a solid financial track record, making it an intriguing stock for AI-focused investors Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot